The HLA-A*31:01 allele: influence on carbamazepine treatment

References

• MarsonAGAl-KharusiAMAlwaidhMThe SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trialLancet200736995661000101517382827
   PubMed Web of Science ®Google Scholar
• BaftiuAJohannessen LandmarkCRustenIRFeetSAJohannessenSILarssonPGChanges in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders-a pharmacoepidemiological study and clinical implicationsEur J Clin Pharmacol201672101245125427411937
   PubMed Web of Science ®Google Scholar
• YipVLMarsonAGJorgensenALPirmohamedMAlfirevicAHLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic reviewClin Pharmacol Ther201292675776523132554
   PubMed Web of Science ®Google Scholar
• SekulaPDunantAMockenhauptMComprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysisJ Invest Dermatol201313351197120423389396
   PubMed Web of Science ®Google Scholar
• QuirkeKPBeckAGamelliRLMosierMJA 15-year review of pediatric toxic epidermal necrolysisJ Burn Care Res201536113013625501779
   PubMed Web of Science ®Google Scholar
• ChungW-HHungS-IHongH-SMedical genetics: a marker for Stevens-Johnson syndromeNature2004428698248615057820
   PubMed Web of Science ®Google Scholar
• McCormackMAlfirevicABourgeoisSHLA-A*3101 and carbamazepine-induced hypersensitivity reactions in EuropeansN Engl J Med2011364121134114321428769
   PubMed Web of Science ®Google Scholar
• OzekiTMushirodaTYowangAGenome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepineinduced cutaneous adverse drug reactions in Japanese populationHum Mol Genet20112051034104121149285
   PubMed Web of Science ®Google Scholar
• The M. H. C. Sequencing ConsortiumComplete sequence and gene map of a human major histocompatibility complexNature1999401675692192310553908
   PubMed Web of Science ®Google Scholar
• CaronEKowalewskiDJChiek KohCSturmTSchusterHAebersoldRAnalysis of major histocompatibility complex (MHC) immunopeptidomes using mass spectrometryMol Cell Proteomics201514123105311726628741
   PubMed Web of Science ®Google Scholar
• ManCBLKwanPBaumLAssociation between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han ChineseEpilepsia20074851015101817509004
   PubMed Web of Science ®Google Scholar
• WuXTHuFYAnDMAssociation between carbamazepineinduced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central ChinaEpilepsy Behav201019340540820833111
   PubMed Web of Science ®Google Scholar
• TassaneeyakulWTiamkaoSJantararoungtongTAssociation between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai populationEpilepsia201051592693020345939
   PubMed Web of Science ®Google Scholar
• ThenSMRaniZZMRaymondAARatnaningrumSJamalRFrequency of the HLA-B*1502 allele contributing to carbamazepineinduced hypersensitivity reactions in a cohort of Malaysian epilepsy patientsAsian Pac J Allergy Immunol201129329029322053601
   PubMed Web of Science ®Google Scholar
• MehtaTYPrajapatiLMMittalBAssociation of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among IndiansIndian J Dermatol Venereol Leprol200975657958219915237
   PubMed Web of Science ®Google Scholar
• ChenPLinJ-JLuC-SCarbamazepine-induced toxic effects and HLA-B*1502 screening in TaiwanN Engl J Med2011364121126113321428768
   PubMed Web of Science ®Google Scholar
• FerrellPBMcLeodHLCarbamazepine, HLA-B*1502 and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendationsPharmacogenomics20089101543154618855540
   PubMed Web of Science ®Google Scholar
• LeckbandSGKelsoeJRDunnenbergerHMClinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and carbamazepine dosingClin Pharmacol Ther201394332432823695185
   PubMed Web of Science ®Google Scholar
• HungS-IChungW-HJeeS-HGenetic susceptibility to carbamazepine-induced cutaneous adverse drug reactionsPharmacogenet Genomics200616429730616538176
   PubMed Web of Science ®Google Scholar
• KashiwagiMAiharaMTakahashiYHuman leukocyte antigen genotypes in carbamazepine-induced severe cutaneous adverse drug response in Japanese patientsJ Dermatol2008351068368519017052
   PubMed Web of Science ®Google Scholar
• NiiharaHKakamuTFujitaYKanekoSMoritaEHLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese populationJ Dermatol201239759460122211527
   PubMed Web of Science ®Google Scholar
• GeninEChenDPHungSIHLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysisPharmacogenomics J201414328128824322785
   PubMed Web of Science ®Google Scholar
• KimS-HLeeKWSongW-JCarbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in KoreansEpilepsy Res2011971–219019721917426
   PubMed Web of Science ®Google Scholar
• AmstutzURossCJDCastro-PastranaLIHLA-A*31:01 and HLA-B*15:02 as genetic markers for carbamazepine hypersensitivity in childrenClin Pharmacol Ther201394114214923588310
   PubMed Web of Science ®Google Scholar
• AnjumNPolakMEArdern-JonesMCooperHLPresence of the HLA-A*3101 allele in a familial case of drug reaction with eosinophilia and systemic symptoms, secondary to carbamazepineClin Exp Dermatol201439330730924635066
   PubMed Web of Science ®Google Scholar
• ShirzadiMThorstensenKHeldeGMoenTBrodtkorbEDo HLA-A markers predict skin-reactions from aromatic antiepileptic drugs in a Norwegian population? a case control studyEpilepsy Res20151185926555631
   PubMed Web of Science ®Google Scholar
• PirmohamedMFriedmannPSMolokhiaMPhenotype standardization for immune-mediated drug-induced skin injuryClin Pharmacol Ther201189689690121562486
   PubMed Web of Science ®Google Scholar
• SchrijversRGilissenLChiriacAMDemolyPPathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and backClin Transl Allergy201553126339470
   PubMed Web of Science ®Google Scholar
• MayTWKorn-MerkerERambeckBClinical pharmacokinetics of oxcarbazepineClin Pharmacokinet200342121023104212959634
   PubMed Web of Science ®Google Scholar
• DamMEkbergRLoyningYWaltimoOJakobsenKA double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsyEpilepsy Res19893170762645120
   PubMed Web of Science ®Google Scholar
• BuggyYLaytonDFoggCShakirSASafety profile of oxcarbazepine: results from a prescription-event monitoring studyEpilepsia201051581882920132298
   PubMed Web of Science ®Google Scholar
• MoonJKimTJLimJAHLA-B*40:02 and DRB1*04:03 are risk factors for oxcarbazepine-induced maculopapular eruptionEpilepsia201657111879188627666425
   PubMed Web of Science ®Google Scholar
• PichlerWJDelayed drug hypersensitivity reactionsAnn Intern Med2003139868369314568857
   PubMed Web of Science ®Google Scholar
• ParkBKNaisbittDJGordonSFKitteringhamNRPirmohamedMMetabolic activation in drug allergiesToxicology20011581–2112311164988
   PubMed Web of Science ®Google Scholar
• PichlerWJBeelerAKellerMPharmacological interaction of drugs with immune receptors: the p-i conceptAllergol Int2006551172517075282
   PubMedGoogle Scholar
• IllingPTVivianJPDudekNLImmune self-reactivity triggered by drug-modified HLA-peptide repertoireNature2012486740455455822722860
   PubMed Web of Science ®Google Scholar
• PichlerWJPharmacological interaction of drugs with antigen-specific immune receptors: the p-i conceptCurr Opin Allergy Clin Immunol20022430112130944
   PubMed Web of Science ®Google Scholar
• YipVMaggsJMengXMarsonAParkKPirmohamedMCovalent adduction of carbamazepine 10, 11-epoxide with human serum albumin and glutathione S-transferase pi: implications for carbamazepine hypersensitivityLancet2014383S114
   Web of Science ®Google Scholar
• WeiCYChungWHHuangHWChenYTHungSIDirect interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndromeJ Allergy Clin Immunol201212961562.e51569.e522322005
   PubMed Web of Science ®Google Scholar
• ZhouPZhangSWangYYangCHuangJStructural modeling of HLA-B*1502/peptide/carbamazepine/T-cell receptor complex architecture: implication for the molecular mechanism of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysisJ Biomol Struct Dyn201634813325565373
   PubMed Web of Science ®Google Scholar
• KoTMChungWHWeiCYShared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndromeJ Allergy Clin Immunol201112861266.e111276.e1121924464
   PubMed Web of Science ®Google Scholar
• ChungWHHungSIYangJYGranulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysisNature medicine2008141213431350
   PubMed Web of Science ®Google Scholar
• LichtenfelsMFarrellJOgeseMOHLA restriction of carbamazepine-specific T-Cell clones from an HLA-A*31:01-positive hypersensitive patientChem Res Toxicol201427217517724476427
   PubMed Web of Science ®Google Scholar
• AmstutzUShearNHRiederMJRecommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactionsEpilepsia201455449650624597466
   PubMed Web of Science ®Google Scholar
• PlumptonCOYipVLAlfirevicAMarsonAGPirmohamedMHughesDACost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsyEpilepsia201556455656326046144
   PubMed Web of Science ®Google Scholar
• PowellGHolmesEAPlumptonCOPharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients’ and physicians’ preferences for testing and service deliveryBr J Clin Pharmacol20158051149115926138622
   PubMed Web of Science ®Google Scholar
• Garcia-DovalILeCleachLBocquetHOteroXLRoujeauJCToxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?Arch Dermatol2000136332332710724193
   PubMedGoogle Scholar
• McCormackMUrbanTJShiannaKVGenome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactionsPharmacogenomics201213439940522379998
   PubMed Web of Science ®Google Scholar
• ChenZLiewDKwanPEffects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactionsNeurology201483222077208425355835
   PubMed Web of Science ®Google Scholar
• IllingPTMifsudNAPurcellAWAllotype specific interactions of drugs and HLA molecules in hypersensitivity reactionsCurr Opin Immunol201642314027261882
   PubMed Web of Science ®Google Scholar
• The Academy of Medical SciencesRealising the Potential of Stratified MedicinesLondonThe Academy of Medical Sciences2013
   Google Scholar
• MallalSNolanDWittCAssociation between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavirLancet2002359930872773211888582
   PubMed Web of Science ®Google Scholar
• HetheringtonSHughesARMostellerMGenetic variations in HLA-B region and hypersensitivity reactions to abacavirLancet200235993121121112211943262
   PubMed Web of Science ®Google Scholar
• HungS-IChungW-HLiouL-BHLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinolProc Natl Acad Sci U S A2005102114134413915743917
   PubMed Web of Science ®Google Scholar
• KaniwaNSaitoYAiharaMHLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysisPharmacogenomics20089111617162219018717
   PubMed Web of Science ®Google Scholar
• HautekeeteMLHorsmansYVan WaeyenbergeCHLA association of amoxicillin-clavulanate-induced hepatitisGastroenterology199911751181118610535882
   PubMed Web of Science ®Google Scholar
• LucenaMIAndradeRJStephensCSusceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class i and II allelesGastroenterology2011141133834721570397
   PubMed Web of Science ®Google Scholar
• DalyAKDonaldsonPTBhatnagarPHLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillinNat Genet200941781681919483685
   PubMed Web of Science ®Google Scholar
• KazeemGRCoxCAponteJHigh-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patientsPharmacogenet Genomics200919966119668019
   PubMed Web of Science ®Google Scholar
• MartinAMNolanDJamesIPredisposition to nevirapine hypersensitivity associated with HLA-DRB1 0101 and abrogated by low CD4 T-cell countsAIDS2005191979915627041
   PubMed Web of Science ®Google Scholar
• ChantarangsuSMushirodaTMahasirimongkolSHLA-B 3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patientsPharmacogenet Genomics200919213919104471
   PubMed Web of Science ®Google Scholar
• CarrDFChapondaMJorgensenALAssociation of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected populationClin Infect Dis20135691330133923362284
   PubMed Web of Science ®Google Scholar
• LocharernkulCLoplumlertJLimotaiCCarbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai populationEpilepsia200849122087209118637831
   PubMed Web of Science ®Google Scholar
• Gonzalez-GalarzaFFTakeshitaLYSantosEJNew features for HLA epitopes, KIR and disease and HLA adverse drug reaction associationsNucleic Acid Research201528D784788 Available from: http://www.allelefrequencies.net/default.aspAccessed October 31, 2016
   Web of Science ®Google Scholar
• Tegretol Prolonged Release 200 mg and 400 mg Tablets (formerly Tegretol retard)CamberleyElectronic Medicines Compendium website2011 [updated September 14, 2016]. Available from: http://www.medicines.org.uk/emc/medicine/24201Accessed December 2, 2016
   Google Scholar